SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas

SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% Fast Track Designation Accelerates SLS009 ' s Path to U.S....
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials